TapewireFind a company

person · Reporting owner

GOEL DAVID E.

Disclosed activity across 6 companies

Tapewire entity
48316
SEC CIK
0001548144

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALUMIS INC.ALMS · Entity 4816Director · 10% owner · See RemarksMay 21, 2025May 23, 2025
Adaptive Biotechnologies CorpADPT · Entity 1126Director · See RemarksMarch 08, 2021March 11, 2021
POPULAR, INC.BPOP · Entity 1363DirectorMay 08, 2018May 10, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALUMIS INC.

Report date May 21, 2025 · Filed May 23, 2025

Jointly reported with AyurMaya Capital Management Company, LP

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.0001 per share ("Common Stock")SEC Table I · non-derivativeIndirectSee footnotes15,139,707 Reported balance After 2025-05-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-05-21 · Grant · Acquired 4,493,741 · Balance 15,139,707

F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement.

F2: Reflects the estimated number of shares of Common Stock to be issued to the AyurMaya Fund (as defined below) pursuant to the Merger Agreement. The Reporting Persons will file an amendment to this Form 4 to the extent the actual number of shares of Common Stock issued differs in any material respect from the number reported in column (4).

F3: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement.

F2: Reflects the estimated number of shares of Common Stock to be issued to the AyurMaya Fund (as defined below) pursuant to the Merger Agreement. The Reporting Persons will file an amendment to this Form 4 to the extent the actual number of shares of Common Stock issued differs in any material respect from the number reported in column (4).

F3: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Adaptive Biotechnologies Corp

Report date March 08, 2021 · Filed March 11, 2021

Jointly reported with Matrix Capital Management Company, LP

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnotes12,309,090 Last balance in matching sequence After 2021-03-10 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
9 source rows

Row 1 · 2021-03-08 · Sale · Disposed 234,295 · Balance 12,880,795

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 2 · 2021-03-08 · Sale · Disposed 75,000 · Balance 12,805,795

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 3 · 2021-03-08 · Sale · Disposed 33,600 · Balance 12,772,195

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 4 · 2021-03-08 · Sale · Disposed 71,194 · Balance 12,701,001

F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 5 · 2021-03-08 · Sale · Disposed 85,911 · Balance 12,615,090

F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 6 · 2021-03-09 · Sale · Disposed 215,698 · Balance 12,399,392

F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 7 · 2021-03-09 · Sale · Disposed 34,302 · Balance 12,365,090

F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 8 · 2021-03-10 · Sale · Disposed 25,732 · Balance 12,339,358

F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Row 9 · 2021-03-10 · Sale · Disposed 30,268 · Balance 12,309,090

F9: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect1,504 Reported balance Holding disclosure · report date 2021-03-08 · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · Balance 1,504

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F9: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

POPULAR, INC.

Report date May 08, 2018 · Filed May 10, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock Par Value $0.01 per shareSEC Table I · non-derivativeDirect12,828.433 Reported balance After 2018-05-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2018-05-08 · Grant · Acquired 2,133 · Balance 12,828.433

F1: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director.

F2: Includes 122.79 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director.

F2: Includes 122.79 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Jointly reported with AyurMaya Capital Management Company, LP

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.00001 per share ("Common Stock")SEC Table I · non-derivativeIndirectSee footnotes0 Reported balance After 2025-05-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-05-21 · Disposition to issuer · Disposed 9,334,735 · Balance 0

F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding.

F2: The securities reported herein were held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding.

F2: The securities reported herein were held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Aura Biosciences, Inc.

Report date May 07, 2026 · Filed May 11, 2026

Jointly reported with Matrix Capital Management Company, LP

Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.00001 per share (Common Stock)SEC Table I · non-derivativeIndirectSee footnotes0 Reported balance After 2026-05-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-05-07 · Sale · Disposed 6,922,870 · Balance 0

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Zentalis Pharmaceuticals, Inc.

Report date December 15, 2025 · Filed December 15, 2025

Jointly reported with Matrix Capital Management Company, LP

Section 16 reporting ended · disclosed 2025-12-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivativeIndirectSee footnotes6,459,973 Reported balance After 2025-12-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2025-12-15 · Sale · Disposed 7,500,000 · Balance 6,459,973

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 07, 2026 Filed May 11, 2026 20:16 UTC Aura Biosciences, Inc. AURA · Entity 5142 SaleCommon Stock, par value $0.00001 per share (Common Stock) 6,922,870 $5.64 $39,044,986.80
Disclosure

SEC source: 0000950142-26-001346 · es260777872_4-matrix.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
December 15, 2025 Filed Dec 15, 2025 22:24 UTC Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 SaleCommon Stock, par value $0.001 per share 7,500,000 $1.33 $9,975,000.00
Disclosure

SEC source: 0000902664-25-005288 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,459,973

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
May 21, 2025 Filed May 23, 2025 20:20 UTC ALUMIS INC. ALMS · Entity 4816 GrantCommon Stock, par value $0.0001 per share ("Common Stock") 4,493,741 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-25-002532 · ownership.xml · nonDerivative · entry 1

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 15,139,707

F1 · kind: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement.

F2 · shares: Reflects the estimated number of shares of Common Stock to be issued to the AyurMaya Fund (as defined below) pursuant to the Merger Agreement. The Reporting Persons will file an amendment to this Form 4 to the extent the actual number of shares of Common Stock issued differs in any material respect from the number reported in column (4).

F1 · price: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Read SEC document
May 21, 2025 Filed May 23, 2025 20:23 UTC ACELYRIN, Inc. SLRN · Entity 79310 Disposition to issuerCommon Stock, par value $0.00001 per share ("Common Stock") 9,334,735 $0.00 $0.00
Disclosure

SEC source: 0000902664-25-002533 · ownership.xml · nonDerivative · entry 1

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · kind: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding.

F1 · price: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding.

F2 · ownership.nature: The securities reported herein were held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 20:45 UTC ALUMIS INC. NASDAQ · Entity 4816 ConversionSeries C Redeemable Convertible Preferred Stock · Derivative 12,745,916 $0.00 $0.00
Disclosure

SEC source: 0000902664-24-004603 · ownership.xml · derivative · entry 5

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,726,398 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F1 · derivative.exercise_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F1 · derivative.expiration_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 20:45 UTC ALUMIS INC. NASDAQ · Entity 4816 ConversionSeries B-2 Redeemable Convertible Preferred Stock · Derivative 5,336,489 $0.00 $0.00
Disclosure

SEC source: 0000902664-24-004603 · ownership.xml · derivative · entry 4

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,141,494 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F1 · derivative.exercise_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F1 · derivative.expiration_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 20:45 UTC ALUMIS INC. NASDAQ · Entity 4816 ConversionSeries B Redeemable Convertible Preferred Stock · Derivative 20,000,000 $0.00 $0.00
Disclosure

SEC source: 0000902664-24-004603 · ownership.xml · derivative · entry 3

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 4,278,074 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F1 · derivative.exercise_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F1 · derivative.expiration_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 20:45 UTC ALUMIS INC. NASDAQ · Entity 4816 GrantCommon Stock 2,500,000 $16.00 $40,000,000.00
Disclosure

SEC source: 0000902664-24-004603 · ownership.xml · nonDerivative · entry 2

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 10,645,966

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 20:45 UTC ALUMIS INC. NASDAQ · Entity 4816 ConversionCommon Stock, par value $0.0001 per share ("Common Stock") 8,145,966 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-24-004603 · ownership.xml · nonDerivative · entry 1

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,145,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F1 · price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 09, 2023 Filed Nov 9, 2023 21:35 UTC Aura Biosciences, Inc. AURA · Entity 5142 PurchaseCommon Stock, par value $0.00001 per share (Common Stock) 1,560,000 $9.00 $14,040,000.00
Disclosure

SEC source: 0000902664-23-005429 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,922,870

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
June 20, 2023 Filed Jun 20, 2023 20:30 UTC Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 PurchaseCommon Stock, par value $0.001 per share 4,760,000 $22.66 $107,861,600.00
Disclosure

SEC source: 0000902664-23-003642 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 13,959,973

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
May 09, 2023 Filed May 11, 2023 20:10 UTC ACELYRIN, Inc. SLRN · Entity 79310 ConversionSeries C Redeemable Convertible Preferred Stock · Derivative 3,709,429 $0.00 $0.00
Disclosure

SEC source: 0000902664-23-002975 · ownership.xml · derivative · entry 3

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 3,709,429 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock.

F1 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock.

F1 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
May 09, 2023 Filed May 11, 2023 20:10 UTC ACELYRIN, Inc. SLRN · Entity 79310 ConversionSeries B Redeemable Convertible Preferred Stock · Derivative 5,625,306 $0.00 $0.00
Disclosure

SEC source: 0000902664-23-002975 · ownership.xml · derivative · entry 2

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 5,625,306 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock.

F1 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock.

F1 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock.

F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
May 09, 2023 Filed May 11, 2023 20:10 UTC ACELYRIN, Inc. SLRN · Entity 79310 ConversionCommon Stock, par value $0.00001 per share ("Common Stock") 9,334,735 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-23-002975 · ownership.xml · nonDerivative · entry 1

AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · See Remarks

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 9,334,735

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F1 · price: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock.

F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.

F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
December 05, 2022 Filed Dec 7, 2022 21:30 UTC Aura Biosciences, Inc. AURA · Entity 5142 PurchaseCommon Stock, par value $0.00001 per share ("Common Stock") 1,250,000 $12.00 $15,000,000.00
Disclosure

SEC source: 0000902664-22-005061 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 5,362,870

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 02, 2021 Filed Nov 4, 2021 20:44 UTC Aura Biosciences, Inc. AURA · Entity 5142 ConversionSeries E Convertible Preferred Stock · Derivative 2,327,870 $0.00 $0.00
Disclosure

SEC source: 0000902664-21-004738 · ownership.xml · derivative · entry 3

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 2,327,870 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 02, 2021 Filed Nov 4, 2021 20:44 UTC Aura Biosciences, Inc. AURA · Entity 5142 PurchaseCommon Stock 1,785,000 $14.00 $24,990,000.00
Disclosure

SEC source: 0000902664-21-004738 · ownership.xml · nonDerivative · entry 2

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 4,112,870

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
November 02, 2021 Filed Nov 4, 2021 20:44 UTC Aura Biosciences, Inc. AURA · Entity 5142 ConversionCommon Stock, par value $0.00001 per share ("Common Stock") 2,327,870 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-21-004738 · ownership.xml · nonDerivative · entry 1

Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner

GOEL DAVID E. · CIK 0001548144 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,327,870

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 30,268 $42.38 $1,282,664.01
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 9

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,309,090

F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 10, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 25,732 $41.47 $1,067,036.56
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 8

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,339,358

F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 34,302 $41.16 $1,411,887.47
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 7

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,365,090

F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 09, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 215,698 $40.42 $8,719,332.81
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 6

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,399,392

F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 85,911 $41.62 $3,575,753.28
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 5

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,615,090

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 71,194 $41.21 $2,933,641.32
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 4

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,701,001

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 33,600 $39.97 $1,343,039.04
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 3

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,772,195

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 75,000 $39.22 $2,941,162.50
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 2

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,805,795

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
March 08, 2021 Filed Mar 11, 2021 00:45 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 234,295 $38.22 $8,954,309.74
Disclosure

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,880,795

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
February 15, 2021 Filed Feb 18, 2021 02:40 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 GrantStock Option (Right to Buy) · Derivative 3,759 $0.00 Strike: $66.50 $0.00
Disclosure

SEC source: 0000902664-21-001476 · ownership.xml · derivative · entry 2

GOEL DAVID E. · CIK 0001548144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,759

Underlying: Common Stock · 3,759 shares

Expires 2031-02-15

F2 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.

F1 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Read SEC document
February 15, 2021 Filed Feb 18, 2021 02:40 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 GrantCommon Stock 1,504 $0.00 $0.00
Disclosure

SEC source: 0000902664-21-001476 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,504

F1 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Read SEC document
July 20, 2020 Filed Jul 22, 2020 20:15 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 SaleCommon Stock 2,000,000 $40.00 $80,000,000.00
Disclosure

SEC source: 0000902664-20-002761 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 13,115,090

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
February 13, 2020 Filed May 11, 2020 20:15 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 GrantStock Option (Right to Buy) · Derivative 8,888 $0.00 Strike: $31.71 $0.00
Disclosure

SEC source: 0000902664-20-002039 · ownership.xml · derivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,888

Underlying: Common Stock · 8,888 shares

Expires 2030-02-13

F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.

F2 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Read SEC document
January 24, 2020 Filed Jan 28, 2020 21:15 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 2,217,101 $26.50 $58,753,176.50
Disclosure

SEC source: 0000902664-20-000523 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 15,115,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries F-1 Convertible Preferred Stock · Derivative 84,359 $0.00 Strike: $10.67 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 8

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 84,359 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries F Convertible Preferred Stock · Derivative 11,154,116 $0.00 Strike: $8.97 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 7

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 11,154,116 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries E-1 Convertible Preferred Stock · Derivative 5,893,716 $0.00 Strike: $6.04 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 6

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 5,893,716 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionSeries A Convertible Preferred Stock · Derivative 200,000 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 5

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 84,359 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 4

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,332,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 11,154,116 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 3

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,247,832

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 5,893,716 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 2

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 6,093,716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:53 UTC Adaptive Biotechnologies Corp ADPT · Entity 1126 ConversionCommon Stock 200,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 200,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date.

F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Read SEC document
May 08, 2018 Filed May 10, 2018 15:59 UTC POPULAR, INC. BPOP · Entity 1363 GrantCommon Stock Par Value $0.01 per share 2,133 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-029101 · doc4.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,828.433

F1 · kind: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director.

F2 · balance_after: Includes 122.79 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act.

Read SEC document
December 31, 2017 Filed Feb 12, 2018 21:38 UTC POPULAR, INC. BPOP · Entity 1363 OtherCommon Stock Par Value $0.01 per share 120.643 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-009222 · doc5.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,572.643

F1 · kind: Shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act.

Read SEC document
May 23, 2017 Filed May 24, 2017 17:29 UTC POPULAR, INC. BPOP · Entity 1363 GrantCommon Stock Par Value $0.01 per share 2,343 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-034853 · doc4.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,452

F1 · kind: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director.

F2 · balance_after: Includes 69.935 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act.

Read SEC document
December 31, 2016 Filed Feb 13, 2017 12:08 UTC POPULAR, INC. BPOP · Entity 1363 OtherCommon Stock Par Value $0.01 per share 66.202 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-009816 · doc5.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,039.064

F1 · kind: Shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.